Friday, 5 July 2019

Coronary Stents Market - Granular Market Report and Review, 2019

Market Research Future adds the “Coronary Stents Market Research Report - Global Forecast till 2023” report to their unique collection and states that, Global Coronary Stents Market is expected to grow significantly over the forecast period. The market held a market value of USD 9,382.63 Million in 2017 and is projected to grow at a CAGR of 7.81% over the forecast period.
Coronary stents are used in the process of angioplasty to make the cross-section of the blood vessel wider. Stents hold the walls of the vessel and thus do not let it sag or shrink, thereby curing the blockages in the vessel. Coronary stents have substantially changed the practice of interventional cardiology by reducing early complications such as abrupt vessel closure and improving late clinical outcome (restenosis). This results in patient and physician satisfaction. Thus, this factor contributes heavily to the growth of this market.
Moreover, the wide acceptance of prosthesis in coronary artery treatment procedures also fuels the market growth. Key companies are also engaged in new product launches related to coronary stents owing to the wide acceptance of the product. For instance, in May 2018, Terumo Europe NV announced the launch of Ultimaster Tansei drug eluting stent in Europe.
The market, by coronary stents, is further segmented into drug eluting stents, bare metal stents, and bioresorbable vascular scaffolds. Drug-eluting stents are metal stents that have been coated with a pharmacologic drug known to suppress restenosis, whereas bare metal stents are stents without a covering or a coating. Bioresorbable vascular scaffolds are intended to provide mechanical support and drug delivery similar to drug eluting stents, followed by complete resorption in some years.
Key players:
Abbott, B. Braun Melsungen AG, Biotronik SE & Co. KG, Boston Scientific Corporation, C. R. Bard, Inc., Cook Medical, Elixir Medical Corporation, Medtronic plc, Meril Life Sciences, MicroPort Scientific Corporation, Stentys SA, and Terumo Corporation are some of the key players in the global coronary stents market.
Segmentation:
Global Coronary Stents Market has been segmented into products, and end user.Based on products, the market has been segmented into, Drug Eluting Stents, Bare Metal Stents, and Bioresorbable Vascular Scaffolds. The drug eluting stent segment is expected to account for the largest share in the global coronary stents market in 2017. This large share is majorly attributed to the wider acceptance of the drug eluting stents in the angioplasty procedures, better patient compliance as compared to the bare metal stents. On the other hand, bioresorbable stents are projected to grow at the fastest rate during the forecast period. 
European Coronary Stents Market has been segmented into Western Europe and Eastern Europe where-in Western Europe region is further divided into Germany, France, the UK, Italy, Spain, and the rest of Western Europe.  The Coronary Stents Market in Asia-Pacific has been segmented into Japan, China, India, South Korea, Australia, and the rest of Asia-Pacific. The coronary stents market in the Middle East & Africa has been segmented into the Middle East and Africa.
On the basis of end users, the market has been segmented into hospitals & clinics, ambulatory surgical centres, specialty centres, and others. The hospitals & clinics segment is expected to account for the largest share in the global coronary stents market in 2017. At the same time, the increasing establishments of the ambulatory surgical centres in the developed and developing countries has led this segment to grow at the fastest rate during the forecast period.Based on the regions, the market for coronary stents is segmented in to, the Americas, Europe, Asia-Pacific, and the Middle East & Africa. The coronary stents market in the Americas region has further been segmented into North America and South America, where-in the North American market is further divided into the US and Canada.
Browse Complete 130 Pages Premium Research Report Enabled with Respective Tables and Figures @ https://www.marketresearchfuture.com/reports/coronary-stents-market-6938
Regional Market Summary 
Geographically, the Americas is anticipated to dominate the global coronary stents market owing to the rising prevalence of the cardiovascular diseases such as cardiac arrhythmia, arterial blockage, and coronary artery disease among others. The development of the better therapeutic approaches and advanced treatment procedures have affected the growth of the American market in a positive way.
According to the data published by the Department of Health, New York in May 2018, percutaneous coronary intervention is one of the two most common procedures performed on patients with coronary artery disease. Besides this, the high medical awareness among American population, high disposable income, presence of the top medical device manufacturers in the region are some of the many factors that drive the growth of the coronary stents market in this region.
Europe is expected to hold the second largest market share in the global coronary stents market. The market growth in this region is majorly attributed to the increasing government support for the device manufacturers. Geographical expansion of companies has led to the wider reach of the medical products and services which has brought a huge change in terms of the acceptance and implementation of the new products as well as procedures. Similarly, Asia-Pacific region has observed a rapid growth in the coronary stents market owing to the development in the medical sector in developing countries like India and China. Moreover, increase in government funding for healthcare, rising R&D expenditure, and growing number of medical device companies in the region has led to its fastest growth during the forecast period. The Middle East and Africa region is anticipated to show minor growth opportunities in the coronary stents market during the forecast period.

About US:
Market Research Future (MRFR), enable customers to unravel the complexity of various industries through Cooked Research Report (CRR), Half-Cooked Research Reports (HCRR), Raw Research Reports (3R), Continuous-Feed Research (CFR), and Market Research & Consulting Services.
Contact Us:
Market Research Future
Office No. 528, Amanora Chambers
Magarpatta Road, Hadapsar,
Pune - 411028
Maharashtra, India
Phone: +1 646 845 9312
Email: sales@marketresearchfuture.com

Healthcare Asset Management Market - Granular Market Report and Review, 2019

The healthcare asset management market to showcase an extraordinary 18.2% CAGR over the forecast period (2018-2023), revealed Market Research Future (MRFR) in a well-outlined report on the same market.
The healthcare asset management includes patient record management, easy access to maintenance record, locating medical equipment, and registering of the status of each equipment. Increasing demand for healthcare and the availability of varying types of treatment are creating a situation where easy access to everything is prized. This would help in quick and efficient service delivery to patients. When time is of the essence, then keeping everything at a hand’s distance becomes necessary. Healthcare asset management does that quite efficiently. MRFR, while having a detailed study of the healthcare asset management market, harps on segments and their volume-wise and value-wise valuation. In sync, it also analyses the factors that may play an important role in the coming years.
Patient safety gets the priority in the healthcare sector which can provide the much-needed traction to the market. Among the other factors, its ability to simplify the work process can be considered one of the major influencers. In addition, with rising investment in R & D, the sector is only going to flourish. However, accuracy issues and high installation cost can hamper the expected growth rate of the market.
Key Players
  • cenTrak,
  • Airista Flow,
  • GE Healthcare,
  • IBM Corporation,
  • Infor Inc.,
  • Tyco Security Products.,
  • Intelligent InSites,
  • Motorola Solutions, Inc.,
  • Radianse, JADAK (a Novanta Company),
  • Siemens Healthineers, Sonitor Technologies,
  • Stanley Black & Decker, Inc.,
  • Ekahau, Inc.
Segmentation
The healthcare asset management market has been segmented on the basis of product, application, and end-user.
On the basis of product, the market has been classified as real-time location systems (RTLS), radiofrequency identification (RFID) devices and ultrasound & infrared tags. The real-time location systems (RTLS) segment has been further divided into hardware, software and services. The hardware segment has been further divided into tags/badges and readers/interrogators.
The radiofrequency identification (RFID) devices have been classified as hardware, and software and services. the hardware segment has been divided tags, readers/interrogators, and accessories. The tags sub-segment has been segmented into passive tags and active tags. The passive tags segment has been divided into high-frequency (HF) tags, ultra-high-frequency (UHF) tags and low-frequency (LF) tags. Furthermore, the application segment has been sub-segmented into hospital asset management and pharmaceutical asset management. The hospital asset management segment includes equipment tracking and management, patient management, temperature and humidity monitoring, staff management and infection control and hand hygiene compliance. The pharmaceutical asset management segment includes drug anti-counterfeiting and supply chain management.
The market, by end-user, has been segmented into Hospital/Clinic, Laboratories, Pharmaceutical companies, Biotechnology.
The market has been segmented, by region, into the Americas, Europe, Asia-Pacific, and the Middle East & Africa. The healthcare asset management market in the Americas has further been segmented into North America and South America, with the North American market divided into the US and Canada.
The healthcare asset management market in Asia-Pacific has been segmented into Japan, China, India, South Korea, Australia, and the rest of Asia-Pacific. The healthcare asset management market in the Middle East & Africa has been segmented into the Middle East and Africa.
The European healthcare asset management market has been segmented into Western Europe and Eastern Europe. Western Europe has further been classified as Germany, France, the UK, Italy, Spain, and the rest of Western Europe. 
Regional Summary
MRFR included regions such as the Americas, Asia Pacific (APAC), Europe, and the Middle East & Africa (MEA) in their report on the healthcare asset management market.
The Americas is a market that is highly evolved, both infrastructurally and technologically. High investment potential in the region enables various end-users in integrating the healthcare asset management market. These factors are going to play a big role in maintaining the premier position it is enjoying now in the global market.
Europe’s market is the second biggest one where the crisis of counterfeit drugs can be avoided with such effective methods. At the same time, the increasing investment for research and development sector can assure the market of better management technology in the coming years. The regional healthcare sector is relying much on the prosperity of healthcare asset management as it can ease the entire workflow to back the growing demands from patients. The AAPC market is all set to grow with the fastest CAGR during the forecast period. Rapid digitization in the healthcare sector is expected to boost the market. The MEA market can contribute a small part only as the region is technologically not that well-structured.
Browse Complete 85 Pages Premium Research Report Enabled with 90 Respective Tables and Figures @ https://www.marketresearchfuture.com/reports/healthcare-asset-management-market-6335
About US:
Market Research Future (MRFR), enable customers to unravel the complexity of various industries through Cooked Research Report (CRR), Half-Cooked Research Reports (HCRR), Raw Research Reports (3R), Continuous-Feed Research (CFR), and Market Research & Consulting Services.
Contact Us:
Market Research Future
Office No. 528, Amanora Chambers
Magarpatta Road, Hadapsar,
Pune - 411028
Maharashtra, India
Phone: +1 646 845 9312
Email: sales@marketresearchfuture.com

Bone Scan Market Trends and Drivers Analysis 2019 To 2023

According to the WHO, about 59% of the mortality is due to chronic diseases and almost 35 million people die of chronic diseases across the globe.
The global bone scan market is expected to grow at a CAGR of 5.7% during the forecast period.
bone scan is a test of nuclear medicine and is mostly used to diagnose various bone diseases such as arthritis and bone cancer. It includes an injection of radioactive material and then the bone scan. Radioactive material also known as the tracer is injected into a vein. After injecting this material, the radiologist performs a bone scan. The radiologist may perform the bone scan in phases depending upon the condition to be diagnosed such as the presence of bone disease or cancer.
Rising prevalence of bone disease, increasing demand for imaging devices such as MRI, CT scan, SPECT scan, and increasing health care services are accelerating the growth of the market. Furthermore, the increasing expenditure on medical devices influences the market growth. Technological advancements in radiology devices affecting the market growth. However, the efficiency of bone scan may hinder the market growth over the forecast period. Additionally, the bone scan may determine the inaccurate cause of the abnormality.
Key Players in the Global Bone Scan Market   
  • Siemens (U.S.)
  • Hitachi, Ltd. (Japan)
  • Carestream Health, Inc. (U.S.)
  • Samsung Electronics Co., Ltd. (South Korea)
  • Toshiba Corporation. (Japan)
  • Koninklijke Philips N.V. (Netherlands)
  • General Electric Company (U.S.)
Segments of the Global Bone Scan Market
The global bone scan market is segmented on the basis of product, indication, device, and end user.
On the basis of the product, the market is segmented into radiopharmaceuticals and imaging devices. The imaging devices are further segmented into Magnetic Resonance Imaging (MRI), X-ray, Computed Tomography (CT), Single-Photon Emission Computerized Tomography (SPECT), and others.
On the basis of the application, the market is segmented into fractures, arthritis, Paget's disease of bone, cancer originating in bone, and others.
On the basis of the end user, the market is segmented into hospitals, clinics, diagnostic centers, and others.
Regional Analysis
The Americas lead the global bone scan market owing to the rising prevalence of bone disorders in the U.S. Furthermore, increasing demand for diagnostic services in various also influences the market growth. In North America, the U.S. is the largest market followed by Canada. Increasing penetration of orthopedic specialty hospitals and healthcare insurance is adding fuel to the market growth. Furthermore, the concentration of key players in the market along with the availability of various technologically advanced devices is boosting the market growth in the U.S.
Europe is the second largest bone scan market across the globe. The market is accelerated by the extensive use of diagnostic devices for diagnosis of various chronic diseases such as arthritis, diabetes, obesity and others. Furthermore, extensive research and development (R&D) activities carried out by clinical research and academic institutes stimulate the growth of the market. Germany and France contribute to the growth of the market owing to increasing expenditure on R&D and extensive demand for diagnostic devcies.
The Asia Pacific market is expected to grow at the fastest pace due to the high prevalence of chronic disease such as rheumatoid arthritis, osteoarthritis, obesity, diabetes, and other. Additionally, increasing number of bone injuries such as bone fractures boost the growth of the market.  To add further, increasing number of skilled professionals along with increasing awareness about the bone diseases and importance of imaging tests in the diagnosis of bone diseases, and injuries. In Asia Pacific, India and China are holding the largest market share followed by Japan. Increasing expenditure on healthcare and improving healthcare infrastructure in various developing regions of Asia Pacific region are affecting the market growth, positively.
Browse Complete 110 Pages Premium Research Report Enabled with Respective Tables and Figures @ https://www.marketresearchfuture.com/reports/bone-scan-market-5027
         
About US:
Market Research Future (MRFR), enable customers to unravel the complexity of various industries through Cooked Research Report (CRR), Half-Cooked Research Reports (HCRR), Raw Research Reports (3R), Continuous-Feed Research (CFR), and Market Research & Consulting Services.
Contact Us:
Market Research Future
Office No. 528, Amanora Chambers
Magarpatta Road, Hadapsar,
Pune - 411028
Maharashtra, India
Phone: +1 646 845 9312
Email: sales@marketresearchfuture.com

Latest Study Offers Detailed Insights on Liquid Biopsy Market 2019

Biopsy involves extracting a sample of tissue and testing it for the presence of diseases especially cancer. Traditional tissue biopsy is a painful technique and also has a high rate of false results. Moreover the technique is costly, time consuming and not applicable for extracting samples such as those close to vital organs such as heart. Liquid biopsy overcomes these problems of tissue biopsy by using biomarkers present in samples such as blood, urine etc. and thus is a comparatively non-invasive technique. Liquid biopsy also provides greater information about the sample which is real time. The real time data can be used for monitoring and thereby determining the treatment for diseases such as cancer. The greater sensitivity of tissue biopsy coupled with the development of sophisticated detectors with extremely low detection rates have enabled the early detection of diseases which is the holy grail of cancer.
Segmentation:
Global Liquid Biopsy market has been segmented on the basis of biomarker type which comprises of circulating tumor cells (Ctcs), circulating tumor DNA (Ctdna), extracellular vesicles (Evs) and other biomarker. On the basis of application; market is segmented into cancer therapeutic application, reproductive health, and other therapeutic application. On the basis of sample; market is segmented into blood, urine and others. On the basis of end-users; market is segmented into hospitals and laboratories, academic and research centres and others.
Major Players

  • Guardant Health, Inc.,
  • Trovagene, Inc.,
  • RainDance Technologies, Inc.,
  • Agena Bioscience Inc. Inc.,
  • Admera Health,
  • Biocept, Inc.,
  • Circulogene Theranostics,
  • Inivata Ltd.,
  • SAGA Diagnostics AB,
  • Exosome Diagnostics and others.

Drivers
The market drivers for the liquid biopsy market are rising rates of cancer, growing investment in research and development, collaborations between companies and public organizations, rise in geriatric population, rising expenditure on health etc. The factors which are inhibiting the growth of the market includes the prohibitive costs associated with liquid biopsy and the differential awareness and availability between developing and the developed world. However, not all cancer patients benefit from early detection as some cancer types such as brain cancer and prostate cancer may lie dormant for many years. Further liquid biopsy is not all non-invasive as can be seen in case of using spinal fluid as sample.
Also the technique is not applicable to all types of cancer as some cancers such as brain cancer and prostate cancer may lie dormant for many years, and thus are either undetectable or detected very late which robs liquid biopsy of its advantages. Further liquid biopsy is not all non-invasive as can be seen in case of using spinal fluid as sample.

Regional Analysis:
Depending on geographic region, Liquid biopsy market is segmented into four key regions: Americas, Europe, Asia Pacific, and Middle East & Africa. Globally developed countries led by North America is the largest market for Liquid biopsy. Europe is the second-largest market for liquid biopsy. The developing regions market such as Asia pacific region and Middle East & Africa however is rising much faster.
Key findings
  • Circulating tumor cells (CTCs) segment dominates both in terms of market share as well as revenues, contributing approx. 55.48% of the revenue share of the liquid biopsy market.
  • On the basis of the therapeutic application, the segment for Cancer will reflect the highest growth potential, with over 82.83% of the market share by revenues. However, the urine sample segment is anticipated to witness noticeable growth.
  • The market for liquid biopsy is dominated by North America and Europe and this trend will continue. Asia-Pacific market is the fastest growing market and is expected to grow at a CAGR of 29.7% during forecasted period

Browse Complete 171 Pages Premium Research Report Enabled with 248 Respective Tables and Figures at @ https://www.marketresearchfuture.com/reports/liquid-biopsy-market-710


About US:
Market Research Future (MRFR), enable customers to unravel the complexity of various industries through Cooked Research Report (CRR), Half-Cooked Research Reports (HCRR), Raw Research Reports (3R), Continuous-Feed Research (CFR), and Market Research & Consulting Services.
Contact Us:
Market Research Future
Office No. 528, Amanora Chambers
Magarpatta Road, Hadapsar,
Pune - 411028
Maharashtra, India
Phone: +1 646 845 9312
Email: sales@marketresearchfuture.com

Wednesday, 3 July 2019

Plasma Fractionation Market Growth and Restrain Factors Analysis By 2023

Increasing prevalence of immunodeficiency disorders and rising healthcare expenditure are also boosting the plasma fractionation market in the US region. According to the 2018 study published in the Allergy, Asthma & Clinical Immunology journal, the estimated overall prevalence of immunoglobulin A (IgA) deficiency in the US was approximately 1 in 300 to 1 in 500 persons.
In plasma fractionation process protein products are fractionated from human plasma for the prevention, and treatment of life-threatening conditions such as congenital deficiencies, immunologic disorders, and others.
Global Plasma Fractionation Market is expected to grow significantly over the forecast period. It is anticipated that the market held a valuation of USD 18073 million in 2017 and is projected to grow at a CAGR of 6.5% over the forecast period.
Various other factors such as increasing geriatric population, technological advancements, emerging markets in APAC and RoW, rising plasma collection, and increasing prevalence of respiratory and autoimmune disorders are also expected to propel the growth of the market.
However, the emergence of recombinant alternatives, high cost of advanced products, and unfavourable reimbursement policies can hamper the market growth over the forecast period.
Segmentation
The global plasma fractionation market is segmented based on product, application, end user, and region.
The global market for plasma fractionation, by product is segmented into immunoglobulin, coagulation factor concentrates, albumin, protease inhibitors, and others. The immunoglobulin segment is further classified as intravenous immunoglobulin (IVIG), subcutaneous immunoglobulin (SCIG), and others. The coagulation factor concentrates segment is further classified as Factor VIII, Factor IX, Von Willebrand Factor, Prothrombin Complex Concentrate, Fibrinogen Concentrates, and Factor XIII.
Based on application, the market is segmented into immunology, neurology, hematology, critical care, pulmonology, rheumatology, hemato-oncology, and others.
Based on end user, the market is segmented into hospitals & clinics, clinical research laboratories, academic institutes, and others.
In the current scope of the study, the above-mentioned segments are covered into the four global regions, namely the Americas, Europe, Asia-Pacific and the Middle East & African region.
The plasma fractionation market in the Americas has further been segmented into North America and South America, with the North American market divided into the US and Canada.
The European plasma fractionation market has been segmented into Western Europe and Eastern Europe. Western Europe has been classified as Germany, France, the UK, Italy, Spain, and the rest of Western Europe.  The plasma fractionation market in Asia-Pacific has been segmented into Japan, China, India, South Korea, Australia, and the rest of Asia-Pacific. The plasma fractionation market in the Middle East & Africa has been segmented into the Middle East and Africa.
Regional Market Summary
The Americas dominated the global market for plasma fractionation owing to the presence of major market players and increasing prevalence of immunodeficiency disorders within the region. According to the 2018 study published in the Allergy, Asthma & Clinical Immunology journal, the estimated overall prevalence of immunoglobulin A (IgA) deficiency in the US was approximately 1 in 300 to 1 in 500 persons.
In 2017, it was estimated that Europe stood second in the global plasma fractionation market. This can be attributed to the increasing technological advancements, and rising R&D investments.
Asia Pacific was projected to be the fastest growing region in 2017. Increasing healthcare expenditure drives the regional markets of the Asia Pacific region. According to the Australian Institute of Health and Welfare, from 2015 to 2016, the total health expenditure was USD 181 billion. Out of this, USD 69 billion was spent on hospitals, which is a real increase of USD 2 billion from the previous year. During the same years, non-government sources spent USD 55.8 billion on health.
On the other hand, the Middle East and Africa held least share in the global plasma fractionation market due to inadequate economic development, especially within the African region.
Browse Complete 90 Pages Premium Research Report Enabled with Respective Tables and Figures @ https://www.marketresearchfuture.com/reports/plasma-fractionation-market-7397



About US:
Market Research Future (MRFR), enable customers to unravel the complexity of various industries through Cooked Research Report (CRR), Half-Cooked Research Reports (HCRR), Raw Research Reports (3R), Continuous-Feed Research (CFR), and Market Research & Consulting Services.
Contact Us:
Market Research Future
Office No. 528, Amanora Chambers
Magarpatta Road, Hadapsar,
Pune - 411028
Maharashtra, India
Phone: +1 646 845 9312
Email: sales@marketresearchfuture.com

Gene Expression Analysis Market Segmentation Detailed Study with Forecast Up To 2019

The Global Gene Expression Analysis Market is expected to grow significantly over the forecast period. It is estimated that the global gene expression analysis market is expected to hold a market value of USD 3.250 million and register a CAGR ~9.1% during the forecast period of 2018 to 2023. Gene expression analysis is research dedicated towards functional genomics extending the application purview of studying genes and gene transcripts. Synthesizing functional gene products such as functional RNAs and protein species offers insights on how an intact organism survives when a particular gene goes missing. Growth in personalized medicine and technological developments are driving market growth. According to a data published by the Foley & Lardner LLP, Food and Drug Administration (FDA) approved 16 new personalized medicines in 2017. Moreover, the development of genomic databases and increased government funding towards genomics is fueling market growth.
However, the lack of skilled labor and the high cost of instruments may hamper market growth during the assessment period.
Segmentation
The global gene expression analysis market has been segmented into product, services, application, end-user, and region.
The market, on the basis of product, has been segmented into consumables and instruments.
The market, based on consumables, has been further segmented into reagents and DNA chips.
The market, based on instruments, has been further segmented into polymerase chain reaction (PCR), next-generation sequencing (NGS), microarray, Sanger sequencing, and others.
The market, by services, has been segmented into gene expression profiling services, sequencing services, bioinformatics solutions, and others.
The market, by application, has been segmented into drug discovery, diagnosis, research, and others.
The market, by end-user, has been segmented into pharmaceutical & biotechnology companies, academic & research institutes, contract research organizations, and others.
The market has been segmented, by region, into the Americas, Europe, Asia-Pacific, and the Middle East & Africa. The gene expression analysis market in the Americas has further been segmented into North America and South America, with the North American market divided into the US and Canada.
The European gene expression analysis market has been segmented into Western Europe and Eastern Europe. Western Europe has further been classified as Germany, France, the UK, Italy, Spain, and the rest of Western Europe. 
The gene expression analysis market in Asia-Pacific has been segmented into Japan, China, India, South Korea, Australia, and the rest of Asia-Pacific. The gene expression analysis market in the Middle East & Africa has been segmented into the Middle East and Africa.
Key Players
  • GENERAL ELECTRIC COMPANY,
  • Illumina, Inc.,
  • Thermo Fisher Scientific,
  • Bio-Rad Laboratories, Inc.,
  • Hoffmann-La Roche Ltd,
  • Pacific Biosciences of California, Inc.,
  • BGI,
  • PerkinElmer Inc.,
  • Agilent Technologies, Inc.,
  • QIAGEN,
  • Oxford Gene Technology,
  • Eurofins Scientific,
  • Danaher,
  • Genotypic Technology Pvt Ltd,
  • Macrogen Inc.
Regional Market Summary
Geographically, the Americas is anticipated to dominate the global gene expression analysis market owing to the increasing research activities and the rising popularity of gene expression tests. Additionally, the well-developed healthcare sector is anticipated to boost the American gene expression analysis market.
Asia-Pacific is anticipated to be the fastest growing region in the market due to the growing investment from governments in the field of genomics, and continuously developing economies. According to a report published by the International Journal of Social and Developmental Concerns in October 2017, in Malaysia, the growth of the public primary, as well as secondary care facilities, has decreased in the past few years, and it has not kept pace with the rapid urbanization. Thus, such factors restraint the growth of the market in this region. On the other hand, the Middle East & Africa has the least share of the market.
Europe is expected to hold the second largest position in the global gene expression analysis market. The market growth in this region is attributed to the availability of funds for research.
Browse Complete 160 Pages Premium Research Report Enabled with Respective Tables and Figures at @ https://www.marketresearchfuture.com/reports/gene-expression-analysis-market-7805

About US:
Market Research Future (MRFR), enable customers to unravel the complexity of various industries through Cooked Research Report (CRR), Half-Cooked Research Reports (HCRR), Raw Research Reports (3R), Continuous-Feed Research (CFR), and Market Research & Consulting Services.
Contact Us:
Market Research Future
Office No. 528, Amanora Chambers
Magarpatta Road, Hadapsar,
Pune - 411028
Maharashtra, India
Phone: +1 646 845 9312
Email: sales@marketresearchfuture.com

Live Cell Encapsulation Market size and Key Trends in terms of volume and value 2019

Numerous factors such as a high level of research activities in live cell encapsulation technologies and the rising awareness programs in various countries are anticipated to fuel the growth of the market. Moreover, the increasing investments by various public and private organizations have created a lucrative option for many companies to invest in providing new encapsulation techniques, leading to the overall growth of the market. Furthermore, the inclination towards novel drug delivery systems for disease management fuels the growth of the market during the forecast period.
The Global Live Cell Encapsulation Market is expected to grow significantly over the forecast period. It is estimated that the global live cell encapsulation market is expected to register a CAGR ~ 3.22% during the forecast period of 2018 to 2023, with an estimated market value of USD 249.87 million in 2017.
However, the lack of skilled technicians, and ethical and legal issues, and unaffordability of various small-scale companies to enter the market due to high product manufacturing costs are expected to curb the growth of live cell encapsulation market. Moreover, the availability of high-quality raw material is also restraining the growth of the market.
The global live cell encapsulation market is currently dominated by many market players. The key players in the market are involved in new product launches and strategic collaborations to strengthen its market position. For instance, in August 2018, Balchem Italia S.r.l., a wholly owned subsidiary of Balchem Corporation, acquired Bioscreen Technologies, S.r.l., a privately held manufacturer of encapsulated and fermented feed nutrition ingredients. With this, the company aims to expand its position in the market.
The Global Live Cell Encapsulation Market is driven by factors such as rising demand for clinical efficacy of cell encapsulation technologies and growing awareness related to the clinical role of encapsulated cells to treat different chronic diseases. Additionally, encapsulation provides the durability and stability of the nutrient during handling and storage. Thus, such benefits of this technique are luring the competitors to enter the market.
Key Players
Balchem Corporation, Evonik Industries, Merck KGaA, BÜCHI Labortechnik AG, Lycored, Blacktrace Holdings Ltd., Living Cell Technologies, Reed Pacific Pty Limited, MiKroCaps, Biotime, Inc., Neurotech Holdings, LLC, Sernova Corporation, Encapsys, LLC, Sigilon Therapeutics, Inc., and Viacyte, Inc. are some of the key players in the global live cell encapsulation market.
Segmentation
The Global Live Cell Encapsulation Market has been segmented into manufacturing technique, polymer type, and application. The market, based on manufacturing technique, has been segmented into simple dripping, electrostatic dripping, coaxial airflow, rotating disk atomization, and others. The market, by polymer type, has been further segmented into alginate, HEMA-MMA, Chitosan, silica, cellulose sulfate, PAN-PVC, and others. The market, by application, has been segmented into drug delivery, regenerative medicine, cell transplantation, and others. The drug delivery segment is expected to hold a major share owing to the increasing use of live cell encapsulation techniques in drug delivery systems. The segment of regenerative medicine is expected to be the fastest growing segment due to the rising trend and benefits of encapsulation in the tissue engineering field.
The market has been segmented, by region, into the Americas, Europe, Asia-Pacific, and the Middle East & Africa. The live cell encapsulation market in the Americas has further been segmented into North America and Latin America, with the North American market divided into the US and Canada. The European live cell encapsulation market has been segmented into Western Europe and Eastern Europe. Western Europe has further been classified as Germany, France, the UK, Italy, Spain, and the rest of Western Europe. The live cell encapsulation market in Asia-Pacific has been segmented into Japan, China, India, South Korea, Australia, and the rest of Asia-Pacific. The live cell encapsulation market in the Middle East & Africa has been segmented into the Middle East and Africa.
Regional Market Summary
Geographically, the Americas is expected to dominate the global live cell encapsulation market due to the increasing per capita healthcare expenditure, and the heavy adoption of new technology.
Furthermore, rising expenses in research and development by healthcare bodies and the government is anticipated to drive thegrowth of the market in this region. Apart from this, increasing applications of regenerative medicine in the US is expecting to push the growth of live cell encapsulation market. For instance, According to the National Institutes of Health (NIH), approximately 5,00,000 Americans benefit from a transplant each year.
Europe showed a considerable amount of growth in the global live cell encapsulation market. The market growth in this region is because of the presence of a well-established healthcare system and increase in chronic diseases. For instance, according to cancer research UK, there were approximately 9, 921 cases of cancer diagnosed in 2015. Such high rates of cancer are likely to increase demand for the use of next-generation sequencing as well as increase the market demands for monoclonal bodies and cellular research. These factors are expected to have a positive impact on the live cell encapsulation market.
Asia-Pacific is expected to have a sturdy growth rate during the forecast period owing to the huge patient pool of chronic diseases and government initiatives of healthcare reforms. However, less capital investment is restricting the market growth of this region.
On the other hand, the Middle East & Africa has the least share of the market due to the low disposable income. Moreover, the limited adoption of advanced healthcare facilities and limited access to treatment facilities is also expected to drive the growth of the market in the near future.
Browse Complete 160 Pages Premium Research Report Enabled with Respective Tables and Figures at @ https://www.marketresearchfuture.com/reports/live-cell-encapsulation-market-7772


About US:
Market Research Future (MRFR), enable customers to unravel the complexity of various industries through Cooked Research Report (CRR), Half-Cooked Research Reports (HCRR), Raw Research Reports (3R), Continuous-Feed Research (CFR), and Market Research & Consulting Services.
Contact Us:
Market Research Future
Office No. 528, Amanora Chambers
Magarpatta Road, Hadapsar,
Pune - 411028
Maharashtra, India
Phone: +1 646 845 9312
Email: sales@marketresearchfuture.com